Post-earnings recap
Reported
Thu, May 7, 2026
EPS actual
$0.59
EPS est.
$0.73
EPS surprise
-19.40%
1-day move
+0.02%
Soleno Therapeutics reported an EPS of $0.59, which was below expectations, leading to a slight increase in stock price of 0.02%. The lack of revenue data and guidance may leave investors uncertain about the company's future performance. The market's muted reaction suggests that investors may have anticipated the EPS miss.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.59 | N/A | -19.40% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.
Soleno Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases. With a market cap of $3 billion, it operates in the health care sector, where advancements in treatments can significantly impact patient lives and market dynamics.
Last quarter
In the last quarter, Soleno reported an EPS of $0.80, exceeding expectations by 25.39%. The stock reacted positively, gaining 4.72% the following day.
EPS beat streak
0Q
EPS beat rate
63%
Avg EPS surprise
+1923.32%
Avg 1-day reaction
-0.32%
Overall, expectations for Soleno's upcoming earnings are mixed, with no analyst estimates available. Investors will be keen to see if the company can maintain its recent momentum.
Bull case
If Soleno continues to beat EPS estimates and shows strong revenue growth, it could signal robust demand for its therapies and drive the stock higher.
Bear case
Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a negative market reaction.
The print will turn on these.
Q1
What will the EPS be for Q1-2026, and how does it compare to previous quarters?
The EPS figure will be critical in assessing the company's profitability and could influence investor sentiment significantly.
Q2
What is the expected revenue growth for the upcoming quarter?
Revenue growth is essential for understanding the company's market position and future potential, making it a focal point for investors.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Why consensus could be wrong
The Street may be underestimating the potential for Soleno's therapies to gain traction in the market, given their recent successes.
Supporting evidence
The company has a history of surprising on the upside, with a 63% EPS beat rate.
Options pricing suggests a higher expected move than historical averages, indicating potential for volatility.
Recent positive trends in the biotech sector could bode well for Soleno's upcoming performance.
Key risk
If the EPS comes in above $0.85, it could challenge the current cautious sentiment and shift investor expectations.
Pre-commit to what would confirm each case.
This quarter's performance will be closely watched as it could indicate whether the company can sustain its growth trajectory.
Bull confirmed if
An EPS of $0.85 or higher would confirm strong profitability and growth.
Bear confirmed if
An EPS below $0.70 would raise concerns about the company's financial health.
What the market is pricing for the move.
Implied Move
±4.4%
Historical Avg
±2.0%
The options market is pricing in a significant move of about 4.4%, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±5.1% while SLNO has averaged ±2.0% over the last 8 prints — setup is pricing rich.
ATM IV
0.4%
30d HV
91.7%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Soleno beats expectations, history suggests the stock could rise by around 1.6%, confirming the bullish outlook.
In line / cautious
If results are in line but management provides cautious guidance, the stock may see limited movement as investors digest the news.
Miss
A miss could lead to a decline of approximately 1.19%, reflecting investor disappointment and concerns about future performance.
The lines on the call that would change the story.